Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

by | Jun 19, 2024 | Publications

Lancet Oncol. 2024 Jun 14:S1470-2045(24)00282-1. doi: 10.1016/S1470-2045(24)00282-1. Online ahead of print. ABSTRACT BACKGROUND: CASSIOPEIA part 1 demonstrated superior depth of response and prolonged progression-free survival with daratumumab in combination with...